Xinnate Appoints Erik Kinnman as Chairman of the Board
by Anna-Karin Lindqvist
Xinnate utser Erik Kinnman till styrelseordförande
Xinnate får FDAs Fast Track-status för TCP-25 vid behandling av epidermolysis bullosa
Xinnate receives FDA Fast Track Designation for TCP-25 for the Treatment of Epidermolysis Bullosa
Xinnate announces first patient visit has been completed
Xinnate meddelar att första patientbesöket har genomförts10
2025-12-22-First Scientific Publication Reporting Clinical Trial Results for Xinnate’s Proprietary Drug Candidate TCP-25
Xinnate Completes Oversubscribed Share Issue of SEK 38,5m
2025-12-10 Xinnate Receives FDA IND Approval for TCP-25 Enabling Pivotal Phase 2-3 STEP Study in EB
